C37 NEW INSIGHTS IN THE EPIDEMIOLOGY, MANAGEMENT, AND OUTCOMES OF CYSTIC FIBROSIS, ILD, AND RESPIRATORY DISEASE: Treatment Patterns In Non-Cystic Fibrosis Bronchiectasis (ncfb): A 2-Year Assessment Post-Exacerbation

Exclusion criteria were presence of COPD, cystic fibrosis, and congenital bronchiectasis at any time. Top overall NCFB treatments over the 2-year period consisted of bronchodilators (albuterol 53.6%, fluticasone/salmeterol 24.5%, tiotropium bromide 12.8%, budesonide/formoterol fumarate dihydrate 8.6...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Main Authors: Germino, R, Liao, L, Blazer, M, Ogbonnaya, A
Format: Article
Language:English
Subjects:
Antibiotics
Cystic fibrosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Exclusion criteria were presence of COPD, cystic fibrosis, and congenital bronchiectasis at any time. Top overall NCFB treatments over the 2-year period consisted of bronchodilators (albuterol 53.6%, fluticasone/salmeterol 24.5%, tiotropium bromide 12.8%, budesonide/formoterol fumarate dihydrate 8.6%, ipratropium 6.8%), macrolides (azithromycin 63.0%, clarithromycin 10.4%, erythromycin 3.4%), and inhaled antibiotics (tobramycin 4.7%; Table 1).
ISSN:1073-449X
1535-4970